Decibel Therapeutics

Decibel Therapeutics

  • Founded: 2015
  • Location: Boston, MA
  • Employee range: 50 - 200
  • Clinical stage: Clin1b
  • Therapy area: Cisplatin induced hearing loss
  • Drug types: OTO, GEN
  • Lead product: DB-020
  • Product link:
  • Funding: $127M IPO Feb 2021; $82M D Oct 2020; $55M C Jun 2018; Gv investment Jul 2017; $52M A Oct 2015

job board

Short description:

New medicines to protect, restore & repair hearing

Drug notes:

DB-OTO Clin0 OTOF-related hearing loss; AAV-103 RD GJB2-related hearing loss; AAV-104 RD STRC-related hearing loss; AAV-201 RD bilateral vestibulopathy; DB-ATO Clin0 bilateral vestibulopathy; undisclosed RD sensorineural hearing loss

Long description:

Decibel Therapeutics is developing regenerative and gene therapy strategies to restore hearing and balance. Using their proprietary platform that integrates single-cell genomics and bioinformatics, Decibel is developing precision gene therapy technologies. These will be used to selectively replace genes for the treatment of congenital, monogenic hearing loss. They are also working to restore hair cell functionality for the treatment of acquired hearing and balance disorders. Ultimately, Decibel Therapeutics is creating a world of connection for people with hearing and balance disorders.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy